Experimental study of the pharmacokinetics of rifabutin in liposomal form

Abstract

On mongrel male rats studied pharmacokinetics of rifabutin in liposomal form, the relative bioavailability and tissue distribution after intratracheal administration, evaluated pharmacokinetic linearity. To determine rifabutin in plasma and organs were developed and validated HPLC method with UV detection. In the course of the study established a new linear pharmacokinetics of liposomal form of rifabutin dose range 6.5-26 mg/kg, calculate the main pharmacokinetic parameters found that rifabutin intensively distributed in highly vascularized organs, its content in poorly vascularized organs is much lower. After injection the highest concentration of active substance is observed at the injection site, namely the lungs. Relative bioavailability of rifabutin in liposomal form in this experiment was 522%.

Keywords

• рифабутин
• липосомы
• фармакокинетика
• биодоступность
• вэжх
• валидация
• rifabutin
• liposomes
• pharmacokinetics
• bioavailability
• hplc validation